LB Pharmaceuticals Inc(LBRX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -2.98 | Insider Own | 25.84% | Shs Outstand | 28.7M | Perf Week | -3.32% |
| Market Cap | 1.28B | Forward P/E | - | EPS next Y | 5.89% | Insider Trans | - | Shs Float | 23.9M | Perf Month | 4.62% |
| Enterprise Value | 0.96B | PEG | - | EPS next Q | -1.62 | Inst Own | 83.57% | Short Float | 23.26% | Perf Quarter | 1.64% |
| Income | -0.09B | P/S | - | EPS this Y | -80.48% | Inst Trans | 7.72% | Short Ratio | 14.85 | Perf Half Y | 26.32% |
| Sales | 0.00B | P/B | 3.42 | EPS next 5Y | -20.74% | ROA | -14.55% | Short Interest | 5.56M | Perf YTD | 78.08% |
| Book/sh | 11.59 | P/C | 3.9 | EPS past 3/5Y | -15.94% - | ROE | -15.7% | 52W High | -20.97% ($50.16) | Perf Year | 137.37% |
| Cash/sh | 10.16 | P/FCF | - | Sales past 3/5Y | - | ROIC | -25.45% | 52W Low | 176.88% ($14.32) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -132.05% | Gross Margin | - | Volatility(W/M) | 5.83% 6.4% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 2.36 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 15.08 | EPS Q/Q | -689.03% | Profit Margin | - | RSI (14) | 53.11 | Recom | 1.17 |
| Dividend Gr. 3/5Y | - | Current Ratio | 15.08 | Sales Q/Q | - | SMA20 | 6.87% ($37.09) | Beta | 0.8 | Target Price | $58.92 |
| Payout | - | Debt/Eq | 0.02 | Earnings | 2026/8/11 | SMA50 | -5.35% ($41.88) | Rel Volume | 0.63 | Prev Close | $39.34 |
| Employees | 27 | LT Debt/Eq | 0.01 | EPS/Sales Surpr. | -112.77% - | SMA200 | 22.85% ($32.27) | Avg Volume(3M) | 0.37M | Price | $39.64 |
| IPO | 2025/9/11 | Option/Short | Yes/Yes | Trades | 4083 | Volume | 236,352 | Change | 0.76% |
🧠 LB Pharmaceuticals (LBRX) is a clinical-stage biotech company developing treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. Its lead candidate, LB-102, is a methylated derivative of the existing antipsychotic amisulpride, and is currently being advanced through late-stage clinical development in the United States. The company went public on Nasdaq in 2025, securing funding to support its late-stage clinical programs.
Over the past 1 year, roughly in the middle
21% below its 1-year high.
Traded less than usual. That is 63% of its average volume.
LBRX has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -80.5% this year.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
23.3% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #139 of 594 in the industry
Based on market cap of $1B.
NKTR#138 Nektar Therapeutics $1B PER - LBRX#139 LB Pharmaceuticals Inc $1B PER - 
KARD#140 Kardigan Inc $1B PER - 
OMER#141 Omeros Corp $1B PER 12.2 
DRTS#142 Alpha Tau Medical Ltd $1B PER - 
FAQ
What kind of company is LBRX?
LBRX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of LBRX?
The market cap of LBRX is approximately $1.3B, ranking 2,398 within its sector.
What is the 52-week high and low for LBRX?
LBRX has recorded a 52-week high of $50.16 and a low of $14.32.
